e-antigen

e-antigen,

n a peptide present in blood infected with the hepatitis B virus. The e-antigen is indicative of an actively reproducing hepatitis B virus and probable liver damage.
References in periodicals archive ?
Specifically, treatment with BB-HB-331 resulted in a 90% reduction in the levels of hepatitis B surface antigen (HBsAg) and e-antigen (HBeAg), as compared to untreated controls or liver cells treated with a construct that produces unrelated short hairpin RNA (shRNAs).
Hepatitis B e-antigen (HBeAg) and antibodies to hepatitis B e-antigen (anti-HBe) are only tested for when HBsAg is positive (in patients with hepatitis B infection).
During phase 1 we will be able to measure the drug's ability to knock down production of new infectious virus as well as viral proteins, including s-antigen, e-antigen, and the core protein that forms the capsid.
He tested positive for hepatitis B surface antigen, hepatitis B e-antigen, hepatitis B e-antibody, and hepatitis B surface antibody, but negative for both IgG and IgM hepatitis B core antibodies.
These data appear to offer real hope of long-term freedom from this disease, and further bolster the case for using Pegasys as a first line treatment in patients with e-antigen negative chronic hepatitis B.
16) Once again, adsorption was possible with both E-antigen positive cells and E-antigen negative cells.
These results were found in both HBV e-antigen (HBeAg)-positive and HBeAg-negative patients enrolled in the study of 1,367 patients, Dr.
The QUASH studies are international, multi-center, randomized, double-blind clinical trials of 30mg once daily clevudine compared with 10mg once daily adefovir for 96 weeks in patients with chronic hepatitis due to infection with e-antigen positive hepatitis B virus (QUASH 305) or e-antigen positive (QUASH 306) who have never been treated with drugs of the nucleoside class.
Of the 19 who were HBsAg positive, 9 were e-antigen positive (7 out of 9 had HBV DNA).
The primary efficacy endpoint of the GLOBE study was therapeutic response at one year, a composite endpoint coupling viral suppression (serum HBV DNA suppression below 100,000 copies/mL) with either improved liver disease markers (ALT normalization) or loss of detectable hepatitis B e-antigen (HBeAg).
The relationship between early viral suppression and good 1-year outcomes applied regardless of whether patients were positive or negative for hepatitis B e-antigen (HBeAg) at baseline.
Data show that lamivudine therapy produces a sustained seroconversion (the disappearance of HBV e-antigen and the detection of the antibody to the HBV e-antigen) in only 16% of Asian patients.